|
| 36757526 | Do animal models of brain tumors replicate human peritumoral edema? a systematic literature search. | J Neurooncol | 2023 |
| 37085049 | Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. | J Infect | 2023 |
| 37055303 | Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]. | J Infect | 2023 |
| 36859649 | Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. | Breast Cancer Res Treat | 2023 |
| 34844889 | The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC. | Clin Breast Cancer | 2022 |
| 35800293 | A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigoâ¿¢) in breast cancer patients with BONe metastases: CARBON trial results. | J Bone Oncol | 2022 |
| 35405168 | Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. | J Infect | 2022 |
| 35439304 | Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. | Cancer Immunol Res | 2022 |
| 35702414 | Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial. | Ecancermedicalscience | 2022 |
| 35671774 | Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. | Lancet Oncol | 2022 |
| 35552364 | Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. | JAMA Oncol | 2022 |
| 32835356 | Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34â¿¿640 Patients in the ACCENT Database. | J Natl Cancer Inst | 2021 |
| 33850304 | Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. | Br J Cancer | 2021 |
| 34850894 | Cancer Treatment: Preclinical & Clinical. | J Natl Cancer Inst Monogr | 2021 |
| 34043927 | Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. | Expert Opin Biol Ther | 2021 |
| 32161368 | Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. | Br J Cancer | 2020 |
| 31964373 | Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre. | BMC Cancer | 2020 |
| 31782589 | Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis. | Breast J | 2020 |
| 32035020 | Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. | Lancet Oncol | 2020 |
| 31941523 | CApecitabine plus Radium-223 (Xofigoâ¿¢) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial. | Trials | 2020 |
| 33072895 | CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. | Clin Transl Radiat Oncol | 2020 |
| 32572174 | Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. | Br J Cancer | 2020 |
| 32897732 | Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms. | JCO Glob Oncol | 2020 |
| 32641747 | Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. | Sci Rep | 2020 |
| 30783204 | A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. | Br J Cancer | 2019 |
| 31302407 | Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance. | Crit Rev Oncol Hematol | 2019 |
| 31189729 | Cellular Uptake and Efflux of Palbociclib In Vitro in Single Cell and Spheroid Models. | J Pharmacol Exp Ther | 2019 |
| 31074641 | ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. | Future Oncol | 2019 |
| 30976844 | Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. | Cancer Chemother Pharmacol | 2019 |
| 29119333 | Physiologically Based Pharmacokinetic Modelling of Cytochrome P450Â 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam. | Eur J Drug Metab Pharmacokinet | 2018 |
| 29618616 | Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. | Clin Cancer Res | 2018 |
| 29525430 | The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. | Clin Breast Cancer | 2018 |
| 29329006 | Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. | Cancer Treat Rev | 2018 |
| 29298869 | Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. | Sci Transl Med | 2018 |
| 28550999 | Process mining routinely collected electronic health records to define real-life clinical pathways during chemotherapy. | Int J Med Inform | 2017 |
| 28360015 | Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. | Eur J Cancer | 2017 |
| 28573005 | Drug delivery in a tumour cord model: a computational simulation. | R Soc Open Sci | 2017 |
| 28884461 | Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. | Breast Cancer Res Treat | 2017 |
| 28612225 | Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. | Breast Cancer Res Treat | 2017 |
| 26783036 | Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling. | Breast Cancer Res Treat | 2016 |
| 27392074 | The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study. | PLoS One | 2016 |
| 27441152 | Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. | Springerplus | 2016 |
| 27225692 | A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma. | Clin Cancer Res | 2016 |
| 27398025 | Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. | Breast Cancer (Auckl) | 2016 |
| 26858337 | Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. | J Clin Oncol | 2016 |
| 26857987 | Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer. | Crit Rev Oncol Hematol | 2016 |
| 26852132 | Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer. | Breast Cancer Res | 2016 |
| 26734784 | 'Tablet burden' in patients with metastatic breast cancer. | Eur J Cancer | 2016 |
| 27050076 | Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro. | Oncotarget | 2016 |
| 25595934 | Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. | Ann Oncol | 2015 |